The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Results from the phase I study of a novel CD19/CD20 tandem CAR T-cell therapy in R/R B-cell NHL

Dec 9, 2020
Share:

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Peter Borchmann, University Hospital Cologne, Cologne, DE, about the results from the phase I study of a novel CD19/CD20 tandem chimeric antigen receptor T-cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma.

Results from the phase I study of a novel CD19/CD20 tandem CAR T-cell therapy in R/R B-cell NHL

In this video, Borchmann summarizes the key findings of the phase I trial on MB-CART2019.1, a bispecific tandem chimeric antigen receptor targeting both CD19 and CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Results of this trial are promising, with no dose-limiting toxicities observed.

Share: